Anixa Biosciences (Anixa Biosciences) Float Percentage Of Total Shares Outstanding : 59.81% (As of Apr. 29, 2024)

View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Anixa Biosciences's float shares is 19.08 Mil. Anixa Biosciences's total shares outstanding is 31.90 Mil. Anixa Biosciences's float percentage of total shares outstanding is 59.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Anixa Biosciences's Insider Ownership is 15.90%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Anixa Biosciences's Institutional Ownership is 8.21%.

Anixa Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Anixa Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	19.08	/	31.90
	=	59.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences (Anixa Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118

Website

https://www.anixa.com

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Executives

Amit Kumar	director, officer: Chief Executive Officer	C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani	officer: COO & CFO	12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr	director	6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk	director	3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan	director
David Cavalier	director	C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams	director	C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox	director	929 NOWITA PLACE, VENICE CA 90291
Andrea Belz	director	1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender	officer: Chief Operating Officer	900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman	officer: President and CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop	officer: Sr. Vice President-Engineering	C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson	director	20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams	director	C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747